Teva wins bidding war for Germany’s ratiopharm, beating out Pfizer and Actavis. The purchase gives it the second largest share in the fast-evolving, rough-and-tumble German generics market, as well as a stronger presence in Europe and some emerging markets.
Continue reading "Coming in Friday's "The Pink Sheet" DAILY - Teva Wins Battle To Buy ratiopharm " »
AstraZeneca’s emerging markets ambitions take on a new dimension as the company today announced an 18-drug, nine-territory branded generics alliance with India’s Torrent Pharmaceuticals.
Continue reading "Coming in Friday's "The Pink Sheet" DAILY - AstraZeneca Forms Branded Generics Alliance With India's Torrent Pharmaceuticals " »
Congressman Sander Levin becomes interim chair of House Ways and Means Committee after Rep. Charles Rangel steps down due to ethics violations. Levin, D-Mich. has a record of supporting U.S. intellectual property protection abroad and promoting access to generic drugs in needy populations as former Trade Subcommittee chairman.
Continue reading "Coming in Friday's "The Pink Sheet" DAILY - Rep. Sander Levin takes helm of House Ways and Means Committee" »
President Obama meets with administration officials and Democrat and Republican leaders of the House and Senate during the anticiapted bipartisan health care reform summit, where both sides will try and find some common ground to move legislation forward.
Continue reading "Coming in Friday's "The Pink Sheet" DAILY - President Obama Meets with Congressional Leaders to push forward health care reform bill" »
Shire said it hopes to launch its Gaucher disease drug velaglucerase this year and plans to compete with Genzyme’s Cerezyme by pricing its product at $1,350 per 400-unit vial, 15 percent below Cerezyme’s wholesale price. The specialty pharma company also reported in its earnings call that it recorded about 150 patient switches from Genzyme’s Fabrazyme to its Replagal during the fourth quarter due to shortages of the Genzyme drug.
Continue reading "Coming in Monday's "The Pink Sheet" DAILY - Shire plans to price its Gaucher disease drug 15 percent below Cerezyme" »
